ImmunoGen Inc. (IMGN) and ArQule Inc. (NASDAQ:ARQL) Contrasting side by side

Both ImmunoGen Inc. (NASDAQ:IMGN) and ArQule Inc. (NASDAQ:ARQL) are Biotechnology companies, competing one another. We will compare their profitability, analyst recommendations, institutional ownership, risk, dividends, earnings and valuation.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
ImmunoGen Inc. 53.82M 15.87 167.87M -1.03 0.00
ArQule Inc. 22.82M 15.95 14.76M -0.17 0.00

Table 1 highlights ImmunoGen Inc. and ArQule Inc.’s gross revenue, earnings per share (EPS) and valuation.

Profitability

Table 2 has ImmunoGen Inc. and ArQule Inc.’s return on assets, return on equity and net margins.

Net Margins Return on Equity Return on Assets
ImmunoGen Inc. -311.91% -684.8% -43.8%
ArQule Inc. -64.68% -42.7% -23%

Volatility and Risk

ImmunoGen Inc. has a beta of 2.53 and its 153.00% more volatile than S&P 500. In other hand, ArQule Inc. has beta of 1.61 which is 61.00% more volatile than S&P 500.

Liquidity

The current Quick Ratio of ImmunoGen Inc. is 4.6 while its Current Ratio is 4.6. Meanwhile, ArQule Inc. has a Current Ratio of 9.6 while its Quick Ratio is 9.6. ArQule Inc. is better positioned to pay off its short-term and long-term debts than ImmunoGen Inc.

Insider & Institutional Ownership

ImmunoGen Inc. and ArQule Inc. has shares owned by institutional investors as follows: 85.6% and 85.8%. ImmunoGen Inc.’s share owned by insiders are 0.1%. Competitively, insiders own roughly 0.6% of ArQule Inc.’s shares.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
ImmunoGen Inc. -2.36% -12.8% -43.19% -43.49% -11.07% -16.07%
ArQule Inc. -4.31% -11.91% -41.71% -32.77% 133.55% 115.15%

For the past year ImmunoGen Inc. has -16.07% weaker performance while ArQule Inc. has 115.15% stronger performance.

Summary

ArQule Inc. beats on 9 of the 10 factors ImmunoGen Inc.

ImmunoGen, Inc., a clinical-stage biotechnology company, develops targeted anticancer therapeutics. The company develops its products using its antibody-drug conjugate (ADC) technology. The companyÂ’s product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha for the treatment of platinum-resistant ovarian cancer; IMGN529, an ADC that is in Phase 1b/2 clinical trials for B-cell malignancies; coltuximab ravtansine, which is in Phase 2 trials for B-cell malignancies; IMGN779 that is in Phase 1 clinical trials for the treatment of acute myeloid leukemia (AML); and IMGN632, a preclinical CD123-targeting ADC for the treatment of hematological malignancies, including AML. ImmunoGen, Inc. has collaborations with Roche; Bayer HealthCare AG; Sanofi; Biotest AG; Novartis Institutes for BioMedical Research, Inc.; Eli Lilly and Company; Amgen; Takeda Pharmaceutical Company Limited; Merck; and CytomX Therapeutics, Inc. ImmunoGen, Inc. was founded in 1981 and is headquartered in Waltham, Massachusetts.

ArQule, Inc., a biopharmaceutical company, researches and develops therapeutics for the treatment of cancer and rare diseases in the United States. Its lead product candidate is tivantinib (ARQ 197), a small molecule inhibitor of the c-Met receptor tyrosine kinase and its biological pathway, which is in Phase III clinical trial for the treatment of liver cancer. The companyÂ’s clinical-stage products include ARQ 087, a multi-kinase inhibitor of the fibroblast growth factor receptor family Phase II clinical trial for patients with intrahepatic cholangiocarcinoma and in Phase Ib for multiple oncology indications; ARQ 092, an inhibitor of the AKT serine/threonine kinase in Phase I clinical trials for multiple oncology indications; ARQ 751, a next-generation inhibitor of AKT in Phase I clinical trial for solid tumors; and ARQ 761, an intravenously administered analogue of Beta-lapachone, which is Phase 1b clinical trial used as a promoter of NQo1-mediated programmed cancer cell death. Its pre-clinical development program also includes ARQ 531, an inhibitor of BrutonÂ’s tyrosine kinase. The company has co-development and co-commercialization agreement with Daiichi Sankyo Co., Ltd.; license agreement with Kyowa Hakko Kirin Co., Ltd.; and collaborative research and development agreement with Beryllium Development Corp. Arqule, Inc. was founded in 1993 and is headquartered in Burlington, Massachusetts.

"

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.